Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of AEF0117 in Healthy Volunteers
NCT03443895Phase 1Completed
- Sponsor
- Aelis Farma
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cannabis use disorder (CUD) comparing AEF0117 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent AEs and SAEs as assessed by vital signs, Incidence of treatment-emergent AEs and SAEs as assessed by ECGs and 2 more. Started Jan 2018; status: completed.
02
Drugs
aef0117
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03443895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443895.